GSK confirms £250m deal to sell experimental drug to Dermavent Sciences
pharmafile | July 13, 2018 | News story | Medical Communications | Dermavent, GSK, Roivant, tapinarof
British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ subsidiary Dermavent Sciences, in a deal worth up to £250 million.
Dermavent made an initial payment of £150 million for the rights to tapinarof, with an agreed future milestone payment of an additional £100 million if the drug meets developmental targets. Upon completion of the deal, Dermavent will hold the global rights to the experimental drug in all countries except China.
Dr Mayukh Sukhatme, President of Roivant Pharma, commented that: “We are excited to partner with GSK as we pursue the rapid initiation of phase III development for tapinarof. It is the ideal drug to complement Dermavant’s existing pipeline of innovative therapies.”
The drug, which has been studied for its use in treating psoriasis and atopic dermatitis (eczema), demonstrated clinically meaningful results in treating adults with plaque psoriasis in a Phase IIb study involving 227 patients.
The drug also demonstrated efficacy in a separate double-blind placebo controlled phase IIb study of 247 patients with atopic dermatitis.
Dr Jackie Fouse, Executive Chair of Dermavant Sciences, said: “Tapinarof is an investigational therapy that has the potential to provide an important treatment option for psoriasis and atopic dermatitis, conditions affecting millions of patients around the world. This will be the cornerstone of Dermavant’s pipeline, and we are grateful for the opportunity to advance its development.”
The deal has come as GSK places tighter focus on core therapeutic areas. As expanded upon by GSK’s Senior Vice President, R&D pipeline John Lepore: “We have taken a strategic decision to divest or partner medicines in our R&D portfolio that are a better fit for other companies allowing us to concentrate our resources on other promising assets.”
Louis Goss
Related Content
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with …
